<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gonzalez TJ</submitter><funding>NICHD NIH HHS</funding><funding>NIAMS NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | National Institutes of Health</funding><pagination>5947</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9548504</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Recombinant adeno-associated viral (AAV) vectors are a promising gene delivery platform, but ongoing clinical trials continue to highlight a relatively narrow therapeutic window. Effective clinical translation is confounded, at least in part, by differences in AAV biology across animal species. Here, we tackle this challenge by sequentially evolving AAV capsid libraries in mice, pigs and macaques. We discover a highly potent, cross-species compatible variant (AAV.cc47) that shows improved attributes benchmarked against AAV serotype 9 as evidenced by robust reporter and therapeutic gene expression, Cre recombination and CRISPR genome editing in normal and diseased mouse models. Enhanced transduction efficiency of AAV.cc47 vectors is further corroborated in macaques and pigs, providing a str</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing.</pubmed_title><pmcid>PMC9548504</pmcid><funding_grant_id>UH3AR075336</funding_grant_id><funding_grant_id>UH3 AR075336</funding_grant_id><funding_grant_id>R01 HD099486</funding_grant_id><pubmed_authors>Maysonet MS</pubmed_authors><pubmed_authors>Blondel LO</pubmed_authors><pubmed_authors>Fanous MM</pubmed_authors><pubmed_authors>Castellanos Rivera RM</pubmed_authors><pubmed_authors>ElMallah MK</pubmed_authors><pubmed_authors>Oh DK</pubmed_authors><pubmed_authors>Havlik LP</pubmed_authors><pubmed_authors>Gersbach CA</pubmed_authors><pubmed_authors>Asokan A</pubmed_authors><pubmed_authors>Gonzalez TJ</pubmed_authors><pubmed_authors>Piedrahita JA</pubmed_authors><pubmed_authors>Roger AL</pubmed_authors><pubmed_authors>Simon KE</pubmed_authors><pubmed_authors>Smith TJ</pubmed_authors><pubmed_authors>Devlin GW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing.</name><description>Recombinant adeno-associated viral (AAV) vectors are a promising gene delivery platform, but ongoing clinical trials continue to highlight a relatively narrow therapeutic window. Effective clinical translation is confounded, at least in part, by differences in AAV biology across animal species. Here, we tackle this challenge by sequentially evolving AAV capsid libraries in mice, pigs and macaques. We discover a highly potent, cross-species compatible variant (AAV.cc47) that shows improved attributes benchmarked against AAV serotype 9 as evidenced by robust reporter and therapeutic gene expression, Cre recombination and CRISPR genome editing in normal and diseased mouse models. Enhanced transduction efficiency of AAV.cc47 vectors is further corroborated in macaques and pigs, providing a str</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-04T22:36:02.796Z</modification><creation>2024-12-04T12:08:15.342Z</creation></dates><accession>S-EPMC9548504</accession><cross_references><pubmed>36210364</pubmed><doi>10.1038/s41467-022-33745-4</doi></cross_references></HashMap>